Key Highlights
•
A new study shows that for patients with a specific type of lung cancer (EGFR-mutated with co-existing tumor suppressor gene mutations), adding chemotherapy to the targeted drug aumolertinib significantly delays cancer progression compared to using the drug alone. This finding provides the first strong evidence for a more intensive, personalized treatment approach for this group of patients.
Source →
•
A nationwide study in Japan found that lung cancer patients who also have interstitial lung disease live significantly longer when treated with immune checkpoint inhibitors (ICIs) compared to standard chemotherapy, even though the risk of drug-induced lung problems is higher. This means ICIs are a more effective treatment option for these patients, despite the increased side effect risk.
Source →
•
Research reveals that a specific genetic alteration, the loss of the MTAP gene, is common in lung cancers driven by certain oncogenes and makes these cancers more vulnerable to a new class of drugs called PRMT5 inhibitors. This discovery opens a potential new treatment pathway for a subset of lung cancer patients who may benefit from combining these inhibitors with existing targeted therapies.
Source →
•
An AI model that predicts the risk of death in trauma patients was made more accurate, fair, and applicable across different populations by incorporating patient demographics like age and sex. This improved tool can help doctors make better treatment decisions and ensure medical resources are allocated more equitably in emergency care.
Source →
Stay curious. Stay informed — with
Science Briefing.
This is a one time Briefing, Upgrade to continue.
Upgrade and get 50% Off — Coupon: ERWMCWYU
